Skip to main content
SpringerLink
Log in

Incorrect use of orlistat and sibutramine in clinical practice

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

To investigate how the antiobesity drugs orlistat and sibutramin are prescribed in relation to the approved indications and the Swedish subsidiary rules.

Methods

Anonymous survey to prescribers of a random sample of 2000 out of 20,000 prescription of orlistat and sibutramin.

Results

The response rate was around 65%. About half of the patients were not treated in accordance with the approved indications and a fourth of the patients prescribed sibutramin had one or several contraindications to the drug. The subsidiary rules were not followed in the majority of cases.

Conclusion

Deviation from the approved indications and subsidiary criteria of orlistat and sibutramin is a question of waste of medical and economic resources. Prescribing of sibutramin to patients with contraindications is a serious health hazard.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Summary of product characteristics for orlistat: http://www.emea.eu.int/humandocs/Humans/EPAR/orlistat/orlistat.htm

  2. Summary of product characteristics for sibutramine (in Swedish) http://www.lakemedelsverket.se/

  3. Beermann B, Melander H, Säwe J, Ulleryd C, Dahlqvist R (2001) Incorrect use and limited weight reduction of orlistat (Xenical) in clinical practice. Eur J Clin Pharmacol 57:309–311, DOI 10.1007/s002280100316

    Article  PubMed  CAS  Google Scholar 

  4. http://www.lfn.se/LFNTemplates/Page____453.aspx (in Swedish)

  5. Radley DC, Finkelstein SN, Stafford RS (2006) Off-label prescribing among office-based physicians. Arch Intern Med 66(9):1021–1026

    Article  Google Scholar 

  6. Lasser KE, Seger DL, Yu DT, Karson AS, Fiskio JM, Seger AC, Shah NR, Gandhi TK, Rothschild JM, Bates DW (2006) Adherence to black box warnings for prescription medications in outpatients. Arch Intern Med 166(3):338–344

    Article  PubMed  Google Scholar 

  7. Wagner AK, Chan KA, Dashevsky I, Raebel MA, Andrade SE, Lafata JE, Davis RL, Gurwitz JH, Soumerai SB, Platt R (2006) FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 15(6):369–386

    Article  PubMed  Google Scholar 

  8. Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, Chan KA, Platt R, Schech SD, Ray WA (2000) Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 284(23):3036–3039

    Article  PubMed  CAS  Google Scholar 

  9. Baumann MH, Dellert E (2006) Performance measures and pay for performance. Chest 129:188–191

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Products Agency, P.O. Box 26, 751 03, Uppsala, Sweden

    Anna Dahlin & Björn Beermann

Authors
  1. Anna Dahlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Björn Beermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Björn Beermann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dahlin, A., Beermann, B. Incorrect use of orlistat and sibutramine in clinical practice. Eur J Clin Pharmacol 63, 205–209 (2007). https://doi.org/10.1007/s00228-006-0226-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-006-0226-8

Keywords

Search

Navigation